Financials Haemonetics Corporation

Stocks

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 16:00:02 2026-09-04 EDT			5-day change	1st Jan Change
102.92 ^USD	+0.07%		-0.15%	+28.41%

08-19	Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating	MT
08-18	Haemonetics Shares Rise After Signing Supply Agreement With CSL Plasma	MT

Projected Income Statement: Haemonetics Corporation

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Net sales ¹	993.2	1,169	1,309	1,361	1,334	1,415	1,489	1,580
Change	-	17.67%	12.01%	3.95%	-1.97%	6.05%	5.25%	6.08%
EBITDA ¹	284.9	304.7	370.1	423.3	440.1	450.9	486.7	543.4
Change	-	6.96%	21.46%	14.38%	3.97%	2.46%	7.94%	11.66%
EBIT ¹	187.1	218.4	276.5	326.3	338.5	367.3	396.2	432.8
Change	-	16.73%	26.6%	18%	3.74%	8.5%	7.87%	9.24%
Interest Paid ¹	-17.12	-14.63	-13.02	-24.83	-26.39	-39.65	-38.42	-38.97
Earnings before Tax (EBT) ¹	63.63	141.4	151.9	212.1	128	245.1	280.6	340.9
Change	-	122.23%	7.4%	39.64%	-39.63%	91.41%	14.49%	21.52%
Net income ¹	43.38	115.4	117.6	167.7	97.31	177.4	207.2	239.6
Change	-	166.05%	1.87%	42.64%	-41.97%	82.33%	16.8%	15.6%
Announcement Date	5/10/22	5/11/23	5/9/24	5/8/25	5/7/26	-	-	-

¹USD in Million

Estimates

Fiscal Period: March	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4	2028 Q1	2028 Q2	2028 Q3	2028 Q4	2029 Q1
Net sales ¹	239.9	259.8	265	261.5	297.5	305.3	304.4	311.3	318.2	336.2	343.3	336.2	345.5	348.5	330.6	321.4	327.3	339	346.4	339.4	345	356.7	373.8	356.9	367.7	379.6	381.7	378.6
Change	-	8.28%	2.01%	-1.34%	13.78%	2.63%	-0.29%	2.27%	2.2%	5.68%	2.09%	-2.07%	2.78%	0.88%	-5.15%	-2.78%	1.84%	3.56%	2.18%	-2.01%	1.67%	3.37%	4.8%	-4.53%	3.04%	3.23%	0.56%	-0.81%
EBITDA ¹	61.9	71.05	71.41	64.26	67.68	81.99	76.88	92.78	90.84	96.9	89.24	95.31	107.3	114.4	106.2	104.2	111.9	113.4	110.5	105.5	110.6	113.8	120.3	110.6	120.2	126.3	126.4	-
Change	-	14.77%	0.51%	-10%	5.32%	21.14%	-6.23%	20.68%	-2.09%	6.67%	-7.9%	6.81%	12.59%	6.61%	-7.18%	-1.85%	7.4%	1.33%	-2.62%	-4.51%	4.87%	2.89%	5.68%	-8.04%	8.71%	5.01%	0.15%	-
EBIT ¹	43.79	58.83	46.59	44.89	60.6	59.01	53.94	70.23	68.34	73.36	64.6	71.02	83.5	89.44	82.34	77.55	87.28	89.18	84.5	79.26	90.17	94.6	103.1	88.93	100.1	105.4	101	97.3
Change	-	34.35%	-20.8%	-3.67%	35%	-2.63%	-8.58%	30.19%	-2.69%	7.35%	-11.94%	9.93%	17.58%	7.1%	-7.93%	-5.82%	12.54%	2.18%	-5.24%	-6.2%	13.77%	4.91%	9.01%	-13.76%	12.53%	5.31%	-4.16%	-3.67%
Charge d'intérêts ¹	-4.588	-4.263	-3.872	-5.273	-5.673	-1.055	-2.629	-2.069	-2.471	-1.949	-6.529	-5.643	-6.993	-9.112	-3.157	-6.681	-7.206	-7.421	-5.08	-8.884	-10.54	-10.39	-9.6	-11.12	-8.5	-9.875	-7.75	-
Earnings before Tax (EBT) ¹	19.92	31.39	15.33	25.49	41.06	42.22	32.63	51.59	32.83	44.03	23.41	46.71	44.7	49.92	70.74	45.17	51.28	59.98	-28.4	47.57	63.36	67.7	66.43	58.57	73.38	78.42	70.18	73.5
Change	-	57.55%	-51.17%	66.33%	61.05%	2.84%	-22.73%	58.13%	-36.36%	34.1%	-46.82%	99.51%	-4.3%	11.66%	41.71%	-36.15%	13.54%	16.94%	-147.35%	267.52%	33.18%	6.85%	-1.87%	-11.84%	25.3%	6.87%	-10.51%	4.72%
Net income ¹	14.86	23.23	9.741	19.88	33.2	32.94	29.38	41.04	24.91	31.24	20.37	38.37	33.83	37.49	57.98	34.03	38.68	44.74	-20.15	33.01	43.43	47.23	48.55	42.94	52.68	55.86	53.76	54.79
Change	-	56.38%	-58.07%	104.06%	67.01%	-0.76%	-10.81%	39.68%	-39.31%	25.43%	-34.81%	88.41%	-11.84%	10.83%	54.64%	-41.31%	13.67%	15.66%	-145.03%	263.85%	31.58%	8.74%	2.8%	-11.55%	22.67%	6.05%	-3.77%	1.93%
Announcement Date	11/9/21	2/8/22	5/10/22	8/10/22	11/7/22	2/7/23	5/11/23	8/8/23	11/2/23	2/8/24	5/9/24	8/8/24	11/7/24	2/6/25	5/8/25	8/7/25	11/6/25	2/5/26	5/7/26	8/6/26	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Haemonetics Corporation

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Net Debt ¹	514	481	-	918	979	662	327	-31.3
Change	-	-6.42%	-	-	6.64%	-32.39%	-50.6%	-109.57%
Announcement Date	5/10/22	5/11/23	5/9/24	5/8/25	5/7/26	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Haemonetics Corporation

Fiscal Period: March	2024	2025	2026	2027	2028	2029
CAPEX ¹	66.3	60.39	32.78	33	34	35
Change	-	-8.91%	-45.72%	0.67%	3.03%	2.94%
Free Cash Flow (FCF) ¹	115.5	121.3	260.4	317	335	358
Change	-	5.09%	114.65%	21.72%	5.68%	6.87%
Announcement Date	5/9/24	5/8/25	5/7/26	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Haemonetics Corporation

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Profitability
EBITDA Margin (%)	28.68%	26.07%	28.27%	31.1%	32.99%	31.87%	32.69%	34.4%
EBIT Margin (%)	18.84%	18.69%	21.12%	23.98%	25.37%	25.96%	26.61%	27.4%
EBT Margin (%)	6.41%	12.1%	11.6%	15.58%	9.6%	17.32%	18.84%	21.58%
Net margin (%)	4.37%	9.87%	8.98%	12.32%	7.29%	12.54%	13.92%	15.17%
FCF margin (%)	-	-	8.82%	8.92%	19.52%	22.41%	22.5%	22.66%
FCF / Net Income (%)	-	-	98.21%	72.36%	267.65%	178.67%	161.66%	149.44%
Profitability
ROA	-	-	-	9.96%	9.68%	9.36%	8.95%	8.8%
ROE	17.9%	19.87%	21.4%	26%	29.03%	26.87%	23.18%	20.36%
Financial Health
Leverage (Debt/EBITDA)	1.8x	1.58x	-	2.17x	2.23x	1.47x	0.67x	-
Debt / Free cash flow	-	-	-	7.57x	3.76x	2.09x	0.98x	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	5.06%	4.44%	2.46%	2.33%	2.28%	2.22%
CAPEX / EBITDA (%)	-	-	17.92%	14.27%	7.45%	7.32%	6.99%	6.44%
CAPEX / FCF (%)	-	-	57.42%	49.77%	12.59%	10.41%	10.15%	9.78%
Items per share
Cash flow per share ¹	-	-	-	3.582	6.192	6.344	8.474	-
Change	-	-	-	-	72.86%	2.46%	33.56%	-
Dividend per Share ¹	-	-	-	-	-	1	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	14.68	16.21	-	17.02	16.82	23.38	30.01	37.21
Change	-	10.45%	-	-	-1.22%	39.04%	28.33%	24%
EPS ¹	0.84	2.24	2.29	3.31	2.05	3.963	4.507	5.21
Change	-	166.67%	2.23%	44.54%	-38.07%	93.33%	13.71%	15.61%
Nbr of stocks (in thousands)	51,112	50,448	50,786	50,237	46,471	45,497	45,497	45,497
Announcement Date	5/10/22	5/11/23	5/9/24	5/8/25	5/7/26	-	-	-